H.C. Wainwright maintains buy on VolitionRX with $2.50 target

On Monday, H.C. Wainwright analyst Yi Chen maintained a Buy rating on VolitionRX (NYSE:VNRX) stock, with a steady price target of $2.50, sitting in the middle of the broader analyst range of $2.00 to $5.00. According to InvestingPro data, the stock has declined 9.07% over the past week, despite showing strong revenue growth of 59.1% in the last twelve months. The endorsement follows VolitionRX's recent virtual event, which focused on the progress of its nucleosome profiling platform that's being developed for human cancer diagnostics.

During the event, which took place earlier in the week, VolitionRX presented data that supports the utility of its Nu.Q™ platform in various aspects of cancer management, including lung cancer screening, prognostication, and monitoring, as well as its potential use in multi-cancer applications.

The company also highlighted the expanding licensing opportunities for its Nu.Q Cancer technology. Described as a simple and accessible routine blood test, the technology's growing clinical data is expected to bolster the company's ability to secure additional licensing agreements in the near future.

Chen's commentary underscores the potential of VolitionRX's technology, stating, "We believe that the accumulating clinical data could help the company secure one of more license agreements in the coming quarters." This optimism is reflected in the reiterated Buy rating and price target, suggesting confidence in the company's commercial and clinical development trajectory.

VolitionRX aims to enhance cancer diagnostics through its innovative blood-based tests, which could revolutionize how the disease is detected and monitored. With a focus on licensing opportunities and the clinical data to support its utility, the company is positioned to potentially make significant strides in the cancer diagnostics market. Investors should note that the company's next earnings report is scheduled for May 7, 2025. For deeper insights into VolitionRX's financial health and growth prospects, including additional ProTips and comprehensive analysis, check out the detailed research report available on InvestingPro.

In other recent news, VolitionRx reported a significant revenue increase for Q4 2024, with total revenue reaching $1.2 million, a 59% rise from the previous year, driven by strong sales of its Nu.Q Vet cancer test. Despite this financial performance, the company's cash reserves remain limited, posing potential challenges for future financial stability. In a strategic move, VolitionRx filed a new registration statement with the SEC to manage its share registration effectively, involving no new shares but re-registration of previously accounted shares. Benchmark analysts maintained a Hold rating on VolitionRx, noting the importance of a potential licensing deal that could significantly impact future revenue.

The company also secured $1.8 million in grant funding in early 2025, with the possibility of receiving an additional $4-5 million throughout the year. VolitionRx's efforts to enhance clinical data for various applications, including lung cancer and sepsis, are part of its strategy to monetize its technologies. The company is in discussions to sign licensing agreements in the human space, building on its successful expansion in the veterinary sector. These developments indicate VolitionRx's focus on strengthening its financial position and expanding its market presence in the diagnostics field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.